Answer
Evolocumab (Repatha) is indicated from age 10 years for children with either heterozygous or homozygous familial hypercholesterolaemia.
Sources for this answer
- Repatha SureClickAmgen Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 21Document updated
Sources checked